A retrospective case-series of influence of chronic hepatitis B on synchronous liver metastasis of colorectal cancer

• Published in: Frontiers in oncology Vol. 13; p. 1109464
• Main Authors: Zhu, Lin, Gong, Piqing, Liu, Ye, Shi, Yunjie, Wang, Wenqiang, Zhang, Wei, Hu, Zhiqian, Li, Xinxing
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 23.02.2023
• Subjects: chronic hepatitis B; colorectal cancer; HBV; liver cirrhosis; Oncology; synchronous liver metastasis; chronic hepatitis B; synchronous liver metastasis; colorectal cancer; HBV; liver cirrhosis
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1109464

Our retrospective analysis of a large number of cases found in patients with primary colorectal cancer (CRC) carrying positive HBsAg inhibited the occurrence of synchronous liver metastases (SLM). However, liver cirrhosis caused by non-HBV factors promoted the occurrence of SLM. This study aimed to investigate the effect of HBV on the occurrence of synchronous liver metastases (SLM) of colorectal cancer (CRC). Univariate and multivariate analyses were used to analyze the influence of clinical parameters on the occurrence of SLM. A total of 6, 020 patients with primary CRC were included in our study, of which 449 patients carrying HBsAg(+) accounted for 7.46%. 44 cases of SLM occurred in the HBsAg(+) group, accounting for 9.80%, which was much lower than 13.6% (758/5571) in the HBsAg(-) group (X=5.214, P=0.022). Among CRC patients with HBsAg(-), the incidence of SLM was 24.9% and 14.9% in the group with high APRI and FIB-4 levels, respectively, which were significantly higher than that in the compared groups (12.3% and 12.5%, all P<0.05). Compared with the control group, female patients, late-onset patients, and HBV-infective patients had lower risks of SLM (HR=0.737, 95%CI: 0.614-0.883, P<0.001; HR=0.752, 95%CI: 0.603-0.943, P=0.013; HR=0.682, 95%CI: 0.473-0.961, P=0.034). The carriage of HBsAg(+) status inhibited the occurrence of SLM from CRC. HBV-causing liver cirrhosis did not further influence the occurrence of SLM, whereas non-HBV-factor cirrhosis promoted the occurrence of SLM. Nevertheless, this still required prospective data validation.